NovoCure Ltd (NVCR)
Data as of , from SEC Form 4 filings.
See up to 3 months of NVCR. The 7-day demo opens the 1M and 3M ranges and puts NVCR on your watchlist.
Start 7-day demoLatest NVCR insider trades
About NovoCure Ltd (NVCR)
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
- ST. HELIER
- 1,605
- 2015
- XNAS
NVCR Form 4 activity by transaction type, last 90 days
No Form 4 activity for NVCR in the last 90 days.
NVCR insider transactions (Form 4)
4156 Form 4 filings on record, the earliest from Nov 4, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Uri Weinberg - Officer | Open-market sale | Ordinary Shares | 7,461 footnote F1 | $13.84 footnote F2 | $103K | |
| Uri Weinberg - Officer | Grant or award | Ordinary Shares | 12,992 | $0.00 | - | |
| Uri Weinberg - Officer | Open-market sale | Ordinary Shares | 3,272 footnote F1 | $13.33 footnote F4 | $44K | |
| ||||||
| Michal Nath Puri - Officer | Open-market sale | Ordinary Shares | 1,441 footnote F1 | $13.66 footnote F2 | $20K | |
| ||||||
| Mukund Paravasthu - Officer | Open-market sale | Ordinary Shares | 1,555 footnote F1 | $13.66 footnote F2 | $21K | |
| Mukund Paravasthu - Officer | Open-market sale | Ordinary Shares | 408 footnote F1 | $13.49 footnote F3 | $6K | |
| ||||||
| Nicolas Leupin - Officer | Open-market sale | Ordinary Shares | 1,029 footnote F1 | $13.66 footnote F2 | $14K | |
| ||||||
| Frank X. Leonard - Officer | Open-market sale | Ordinary Shares | 9,734 footnote F1 | $13.66 footnote F2 | $133K | |
| Frank X. Leonard - Officer | Grant or award | Ordinary Shares | 18,621 | $0.00 | - | |
| Frank X. Leonard - Officer | Open-market sale | Ordinary Shares | 7,232 footnote F1 | $13.49 footnote F4 | $98K | |
| ||||||
| Ashley Cordova - Officer | Tax withholding / forfeiture | Ordinary Shares | 11,541 footnote F1 | $13.75 | $159K | |
| Ashley Cordova - Officer | Grant or award | Ordinary Shares | 23,818 | $0.00 | - | |
| Ashley Cordova - Officer | Tax withholding / forfeiture | Ordinary Shares | 2,410 footnote F1 | $13.67 | $33K | |
| Ashley Cordova - Officer | Tax withholding / forfeiture | Ordinary Shares | 7,228 footnote F1 | $13.67 | $99K | |
| ||||||
| Arye Barak Ben - Officer | Grant or award | Ordinary Shares | 17,755 | $0.00 | - | |
 Christoph Brackmann - Officer | Tax withholding / forfeiture | Ordinary Shares | 7,033 footnote F1 | $12.23 | $86K | |
| ||||||
| Mukund Paravasthu - Officer | Tax withholding / forfeiture | Ordinary Shares | 168 footnote F1 | $12.81 | $2K | |
| Mukund Paravasthu - Officer | Tax withholding / forfeiture | Ordinary Shares | 2,949 footnote F1 | $12.23 | $36K | |
| ||||||
| Michal Nath Puri - Officer | Tax withholding / forfeiture | Ordinary Shares | 752 footnote F1 | $12.82 | $10K | |
| ||||||
| Frank X. Leonard - Officer | Tax withholding / forfeiture | Ordinary Shares | 966 footnote F1 | $12.81 | $12K | |
| ||||||
| Ashley Cordova - Officer | Open-market purchase | Ordinary Shares | 81,550 | $12.22 | $997K | |
| Christoph Brackmann - Officer | Open-market purchase | Ordinary Shares | 10,000 | $11.63 | $116K | |
| Christoph Brackmann - Officer | Open-market purchase | Ordinary Shares | 5,000 | $11.60 | $58K | |
| Christoph Brackmann - Officer | Open-market purchase | Ordinary Shares | 5,000 | $11.50 | $58K | |
| Michal Nath Puri - Officer | Grant or award | Ordinary Shares | 833 | $15.13 | $13K | |
| Frank X. Leonard - Officer | Grant or award | Ordinary Shares | 833 | $15.13 | $13K | |
 Asaf Danziger | Grant or award | Ordinary Shares | 833 | $15.13 | $13K | |
| Ashley Cordova - Officer | Grant or award | Ordinary Shares | 833 | $15.13 | $13K | |
| Arye Barak Ben - Officer | Grant or award | Ordinary Shares | 769 | $15.13 | $12K | |
| Gabriel Leung | Grant or award | Ordinary Shares | 11,215 | $0.00 | - | |
| Gabriel Leung | Grant or award | Stock Option (Right to Buy) | 16,697 | $0.00 | - | |
| Jeryl L. Hilleman | Grant or award | Ordinary Shares | 11,215 | $0.00 | - | |
| Jeryl L. Hilleman | Grant or award | Stock Option (Right to Buy) | 16,697 | $0.00 | - | |
| Gabriel Leung | Open-market sale | Ordinary Shares | 999 | $17.31 | $17K | |
| Jeryl L. Hilleman | Open-market sale | Ordinary Shares | 999 | $17.26 | $17K | |
| Mukund Paravasthu - Officer | Open-market sale | Ordinary Shares | 44 | $16.69 | $734 | |
| Mukund Paravasthu - Officer | Grant or award | Ordinary Shares | 30,138 | $0.00 | - | |
| Mukund Paravasthu - Officer | Grant or award | Stock Option (Right to Buy) | 45,620 | $16.59 | $757K | |
| Michal Nath Puri - Officer | Open-market sale | Ordinary Shares | 810 | $15.79 | $13K | |
| Frank X. Leonard - Officer | Open-market sale | Ordinary Shares | 598 | $15.94 | $10K | |
| Mukund Paravasthu - Officer | Open-market sale | Ordinary Shares | 160 | $15.88 | $3K | |
Item 7.01, 9.01
Item 5.02, 9.01
Item 8.01, 9.01
Item 2.02, 9.01
Recent NVCR Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
NVCR insider trading FAQ
What is the latest insider trade for NVCR?
NovoCure Ltd (NVCR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-01. The full record for NVCR runs to 56 Form 4 filings, the earliest from 2024-11-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NVCR stock?
No insider purchases of NVCR were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling NVCR stock?
No insider sales of NVCR were filed in the last 90 days. 31 sales are on record for this company.
Where can I see NVCR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NVCR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michal Nath Puri view on EDGAR
- - Frank X. Leonard view on EDGAR
- - Arye Barak Ben view on EDGAR
- - Asaf Danziger view on EDGAR
- - Frank X. Leonard view on EDGAR
- - Gabriel Leung view on EDGAR
- - Kristin Stafford view on EDGAR
- - Allyson J. Ocean view on EDGAR
- - Timothy J. Scannell view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where NVCR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NVCR with a 7-day demo
- NVCR on your watchlist
- Every NVCR Form 4 filing on record
- Up to 3 months of NVCR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
